Frequency of gestational diabetes mellitus and the associated risk factors among women with polycystic ovary syndrome
Abstract
Background: Polycystic Ovary Syndrome (PCOS) is a significant risk factor for developing Gestational Diabetes Mellitus (GDM). The objective of this study was to determine the frequency of GDM and the associated risk factors among women with PCOS. Methods: This cross-sectional study was done at CMH, Dera Ismail Khan from Aug 2023 to Aug 2024. Participants underwent 75 g Oral Glucose Tolerance Test (OGTT) between 24–28 weeks as part of screening for GDM. Data was analysed on SPSS-24. Shapiro-Wilk test, Mann-Whitney test, Independent t-test, and Chi-square test were applied, and p?0.05 was considered statistically significant. Results: The study included a total of 296 pregnant women with 148 (50.0%) having PCOS and 148 (50.0%) without PCOS. The frequency of GDM was 45.3% and 27.7% among PCOS and non-PCOS women respectively. There existed a significant variation between the GDM and non-GDM groups with reference to the current menstrual status (p<0.001) and menstrual patterns (p=0.007). The use of metformin was significantly associated with reducing the occurrence of GDM (p=0.002). No statistically significant differences were observed in serum levels of LH (p=0.797), FSH, and free testosterone level between the GDM and non-GDM groups. Conclusion: Women with PCOS are at higher risk of developing GDM. GDM screening should be offered at 24–28 weeks in PCOS women with history of irregular menses.
Pak J Physiol 2024;20(3):67–70, DOI: https://doi.org/10.69656/pjp.v20i3.1755
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 296 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.